Who can take part?
Patients with high-risk non-muscle invasive bladder cancer which can also be referred to as HR-NMIBC or urothelial cancer.
What is involved for you?
The research study is testing treatment of HR-NMIBC via an experimental drug delivery system (TAR-200) in combination with a drug called cetrelimab.TAR-200 is a drug delivery system that is placed into the bladder which releases a drug named gemcitabine (an anti-cancer chemotherapy drug) into the bladder. Cetrelimab is a medicine that may treat certain cancers by working with your immune system (it is also known as immunotherapy). Cetrelimab is administered intravenously (into a vein) over a period of as an infusion. 1/3 of patients enrolled in this study will receive TAR-200 combined with cetrelimab, 1/3 with receive the TAR-200 alone and the other 1/3 will receive the standard of care treatment for this condition, called BCG.